Related Experiment Videos
HIV entry and fusion inhibitors
1ICOS Corporation, Bothell, WA 98290, USA. david.chantry@arraybiopharma.com
Expert Opinion on Emerging Drugs
|May 25, 2004
Summary
New human immunodeficiency virus (HIV) therapies target viral entry, offering alternatives to current treatments. This approach addresses drug resistance and toxicity, crucial for combating acquired immunodeficiency syndrome (AIDS).
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS).
- Current therapies target viral enzymes like reverse transcriptase and protease.
- Drug resistance and toxicity necessitate novel HIV treatment strategies.
Purpose of the Study:
- To review recent advancements in therapeutics targeting HIV entry.
- To explore new targets in the viral replication process.
Main Methods:
- Focus on the mechanisms of viral entry into host cells.
- Review of approved and developing HIV fusion inhibitors.
Main Results:
- Identification of viral entry as a key therapeutic target.
- Approval of the first HIV fusion inhibitor, enfuvirtide (T-20).
Conclusions:
- Targeting HIV entry presents a promising new avenue for treatment.
- Development of fusion inhibitors offers an alternative to existing therapies.